| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKACa |
| Uniprot No | P17612 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-351aa |
| 氨基酸序列 | GNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVMLVKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFFADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF |
| 预测分子量 | 41.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKACA重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*"Structural insights into the regulation of human protein kinase A by PRKAR1A and somatic mutations"*
**作者**：Zhang P, et al.
**摘要**：该研究解析了人源PRKACA(蛋白激酶A催化亚基α)与调节亚基PRKAR1A的复合物晶体结构，揭示了PRKACA活性调控机制，并利用重组蛋白分析了肾上腺肿瘤相关突变(如L205R)对激酶活性的影响。
2. **文献名称**：*"Recombinant expression and functional characterization of PRKACA mutations in cortisol-producing adenomas"*
**作者**：Beuschlein F, et al.
**摘要**：通过重组表达PRKACA野生型及突变体(如L206R)，发现突变导致PKA组成性激活，破坏与调节亚基结合，进而异常刺激皮质醇合成，阐明了其在肾上腺腺瘤中的致病机制。
3. **文献名称**：*"Development of a high-yield Escherichia coli system for PRKACA production and its biochemical characterization"*
**作者**：Taylor SS, et al.
**摘要**：报道了一种优化的大肠杆菌重组表达体系，实现PRKACA蛋白高效可溶表达，并通过体外激酶实验验证其催化活性，为PKA信号通路研究提供了可靠工具。
---
*注：文献信息为示例性质，实际引用时建议通过PubMed/Google Scholar以"PRKACA recombinant"等关键词检索最新研究。*
PRKACα (Protein Kinase cAMP-Activated Catalytic Subunit Alpha) is a critical component of the cAMP-dependent protein kinase (PKA) complex, a central regulator of cellular signaling pathways. As one of the catalytic subunits of PKA, PRKACα mediates phosphorylation events that modulate diverse biological processes, including metabolism, gene expression, and cell proliferation. Structurally, it contains two tandem catalytic domains with conserved ATP-binding and substrate recognition motifs. Its activity is tightly regulated by cAMP levels; binding of cAMP to regulatory subunits releases PRKACα, enabling kinase activation.
Recombinant PRKACα proteins are engineered to study its biochemical functions and interactions. Typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems, these proteins retain catalytic activity while allowing precise control over post-translational modifications. Common production strategies involve cloning the *PRKACα* gene into expression vectors with affinity tags (e.g., His-tag) for purification via chromatography. Quality assessments include SDS-PAGE, Western blotting, and kinase activity assays using synthetic peptides like kemptide.
Research applications of recombinant PRKACα span mechanistic studies of cAMP-PKA signaling, disease modeling (e.g., cancers, cardiovascular disorders), and drug discovery. Mutant variants help dissect phosphorylation-dependent pathways or mimic pathogenic mutations linked to endocrine tumors or neural dysfunctions. Additionally, it serves as a tool for high-throughput screening of kinase inhibitors, aiding therapeutic development. The availability of recombinant PRKACα has significantly advanced understanding of PKA’s role in health and disease, offering a versatile platform for both basic and translational research.
×
